BioSpace News Archive

Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the third quarter 2021 after market close on Wednesday, November 3, 2021 at 4:30 PM Eastern Time.

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that it has commenced an underwritten public offering of its ordinary shares and warrants to purchase its ordinary shares.

DOvEEgene - In Canada, it is estimated that endometrial and ovarian cancers affect approximately 10,000 Canadian women per year.

Thermo Fisher Scientific Inc. announced that it has priced an offering of €5.25 billion aggregate principal amount of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific B.V., its indirect, wholly owned finance subsidiary.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that results from the randomized, controlled Phase 3 trial of rexlemestrocel-L in 565 patients with New York Heart Association (NYHA) class II and class III chronic heart failure (CHF) with low ejection fraction (HFrEF) have been selected through peer review as a late breaking presentation at the American Heart Association (AHA) annual meeting.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2021 financial results on Wednesday, November 3, 2021, prior to market open.

Pieris Pharmaceuticals, Inc. today announced the promotions of Thomas Bures to Chief Financial Officer and Ahmed Mousa to Chief Business Officer.

Abcuro, Inc. today announced that a Trial in Progress poster describing a Phase 1 trial of ABC008 will be presented at the Lymphoma, Leukemia and Myeloma Congress Conference being held virtually October 19-23, 2021.

Twist Bioscience Corporation and Centogene N.V. today announced that they have signed a contract to collaborate on the development and commercialization of custom assay kits for rare diseases.

Enanta Pharmaceuticals, Inc. today announced that new preclinical data for EDP-235, its lead oral protease inhibitor specifically designed for the treatment of COVID-19, will be presented at the International Society for Influenza and Other Respiratory Virus Diseases (ISIRV)-World Health Conference on October 19-21, 2021.